One thousand six hundred forty-four patients with metastatic melanoma treated with anti–PD-1 ± IPI at 16 centers from Australia, the United States, and Europe were included. Demographics, disease ...
Expert panelists consider how to define response to disease-modifying therapies and discuss the threshold for treatment ineligibility due to lack of response. Neil Minkoff, MD: At some point, we are ...
Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC). Background: Carcinoembryonic antigen (CEA, CEACAM5) is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback